[go: up one dir, main page]

AR042550A1 - Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina - Google Patents

Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina

Info

Publication number
AR042550A1
AR042550A1 ARP030104736A ARP030104736A AR042550A1 AR 042550 A1 AR042550 A1 AR 042550A1 AR P030104736 A ARP030104736 A AR P030104736A AR P030104736 A ARP030104736 A AR P030104736A AR 042550 A1 AR042550 A1 AR 042550A1
Authority
AR
Argentina
Prior art keywords
memantine
parkinson
alzheimer
release
dosage form
Prior art date
Application number
ARP030104736A
Other languages
English (en)
Inventor
Juan Augusto Vergez
Joaquina Faour
Marcelo A Ricci
Ana Pastini
Original Assignee
Osmotica Argentina S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR042550(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osmotica Argentina S A filed Critical Osmotica Argentina S A
Publication of AR042550A1 publication Critical patent/AR042550A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de dosificación farmacéutica que contiene venlafaxina de liberación controlada en el núcleo en combinación con una droga de liberación rápida anti-Alzheimer o anti-Parkinson en el recubrimiento externo. La memantina es utilizada como droga anti-Alzheimer o anti-Parkinson. En dispositivos osmóticos que poseen perfiles de liberación predeterminados. Una realización del dispositivo osmótico incluye un recubrimiento externo que ha sido recubierto por rocío más que por compresión en el dispositivo. El dispositivo es útil para el tratamiento de la depresión en pacientes con Alzheimer y/o Parkinson. El dispositivo también puede ser utilizados para tratar o mejorar otros síntomas asociados con la enfermedad de Alzheimer, la enfermedad de Parkinson o cualquier otro desorden neurológico. Otras formas de dosificación que proveen una liberación controlada, sostenida o extendida de venlafaxina en combinación con una liberación rápida o inmediata de memantina.
ARP030104736A 2002-12-23 2003-12-19 Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina AR042550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43615602P 2002-12-23 2002-12-23

Publications (1)

Publication Number Publication Date
AR042550A1 true AR042550A1 (es) 2005-06-22

Family

ID=32682351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104736A AR042550A1 (es) 2002-12-23 2003-12-19 Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina

Country Status (5)

Country Link
US (2) US20060062851A1 (es)
EP (1) EP1595535A2 (es)
AR (1) AR042550A1 (es)
AU (1) AU2003302147A1 (es)
WO (1) WO2004056335A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
AR043467A1 (es) * 2003-03-05 2005-07-27 Osmotica Argentina S A Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson
CA2528622C (en) * 2003-05-27 2010-08-03 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
PL2982372T3 (pl) 2005-04-05 2020-12-28 Yale University Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
EP1874282B1 (en) 2005-04-06 2010-09-15 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
ATE489079T1 (de) 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20100081722A1 (en) * 2008-10-01 2010-04-01 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
US20120115943A1 (en) * 2008-10-01 2012-05-10 National Taiwan University Composition and method for neuroprotection against excitotoxic injury
WO2010112221A1 (en) * 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
WO2012101653A2 (en) * 2011-01-25 2012-08-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
WO2013078608A1 (en) * 2011-11-29 2013-06-06 Ziqiang Gu Donepezil pamoate and methods of making and using the same
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
WO2017106584A1 (en) * 2015-12-16 2017-06-22 The Board Of Trustees Of The Leland Stanford Junior University Treatment of central nervous system and mental disorders with agonists of beta-3 adrenoceptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US6838093B2 (en) * 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents

Also Published As

Publication number Publication date
EP1595535A2 (en) 2005-11-16
WO2004056335A3 (es) 2004-11-25
WO2004056335A2 (es) 2004-07-08
US20060062851A1 (en) 2006-03-23
AU2003302147A1 (en) 2004-07-14
US20080175909A1 (en) 2008-07-24
AU2003302147A8 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
AR042550A1 (es) Una forma de dosificacion farmaceutica que comprende venlafaxina y memantina
CO2021008988A2 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
UY27186A1 (es) Formulación farmacéutica
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
MX2019001103A (es) Sistema de suministro transdermico de donepezilo.
CL2008000306A1 (es) Dispositivo para administrar medicamentos que comprende un cuerpo con una matriz de una silicona y un medicamento oftalmico, el cuerpo que tiene una superficie externa, un revestimiento de parileno en una parte de la superficie externa del cuerpo; y
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
DE60325887D1 (de) Pharmazeutische zusammensetzungen zurbehandlung von augenerkrankungen
AR054249A1 (es) Tratamiento de enfermedades del tejido conectivo de la piel
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
CO2020000939A2 (es) Formas de dosificación nasal de dihidroergotamina
AR097997A1 (es) Composición farmaceutica de ibuprofeno y tramadol para uso oftálmico
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
CL2009000322A1 (es) Composicion farmaceutica que comprende flibanserina en su forma amorfa y al menos un excipiente, sistema farmaceutico de liberacion que comprende esta composicion, metodo para fabricar este sistema y su uso para el tratamiento de trastornos del sistema nervioso central, trastornos afectivos, trastornos del sueño y sexuales, entre otros.
ECSP077843A (es) Tratamiento o prevención del prurito
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
BRPI0711246A2 (pt) forma de dosagem de preparação farmacêutica em forma de folha para a terapia da dor, uso de uma forma de dosagem, uso de uma combinação de agentes ativos, método para o tratamento terapêutico da dor e método para a produção de uma forma de dosagem na forma de uma folha
UY28140A1 (es) Una forma de dosificación farmaceutica que comprende venlafaxina y memantina
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR053780A1 (es) Uso de mirtazapina s para la fabricacion de un medicamento para el tratamiento de los bochornos
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
MX2021002686A (es) Formulacion controlada de liberacion de farmacos.
CR9426A (es) Utilizacion de agomelatina para la obtencion de medicamentos destinados al tratamiento de trastornos bipolares
JP2005526713A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure